Skip to content

US · PACB · MEDICAL - DEVICES

Pacific Biosciences of California, Inc. (PACB) intrinsic value and stock valuation

$1.63as of 2026-11-21 · Mkt cap 403.78M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pacific Biosciences of California, Inc. DCF and intrinsic value

InvestorsCraft values PACB with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PACB’s statements →

Pacific Biosciences of California, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Menlo Park, CA 94025 pacb.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$160M+15.2% 5y CAGRd
20112025
Net income
-$-546.38M
20112025
Free cash flow
-$-113.92M
20112025
Total equity
$5.35M-56.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$160M$154M$200.5M$128.3M$130.5M
Operating income-$-557.56M-$-474.31M-$-334.47M-$-307.2M-$-210.44M
Net income-$-546.38M-$-309.85M-$-306.74M-$-314.25M-$-181.22M
EPSd-$-1.82M-$-1.07M-$-1.21M-$-1.4M-$-887.72K
Operating cash flow-$-111.21M-$-206.06M-$-266.55M-$-263.21M-$-111.18M
Capital expenditure-$-2.71M-$-6.19M-$-8.84M-$-16.93M-$-5.93M
Free cash flow-$-113.92M-$-212.25M-$-275.39M-$-280.14M-$-117.11M
Total assets$784.1M$1.26B$1.75B$1.77B$2.01B
Total debt$759.5M$672.4M$933.9M$948.5M$955.4M
Net debt$695.8M$617.1M$754M$623.4M$494.6M
Total equity$5.35M$506.6M$701.3M$562.9M$791M
Cash and short-term investments$279.5M$389.9M$631.4M$772.3M$1.04B
Income statement
20252024202320222021
Revenue$160M$154M$200.5M$128.3M$130.5M
Cost of revenue$109.3M$116.7M$147.7M$79.3M$71.7M
Gross profit$50.7M$37.3M$52.8M$49M$58.9M
Research and development expenses$97.3M$134.9M$187.2M$193M$112.9M
Selling, general and administrative expenses$141.5M$175M$169.8M$160.9M$124.1M
Other expenses$369.4M$201.7M$30.3M$2.38M$32.3M
Operating expenses$608.2M$511.6M$387.3M$356.2M$269.3M
Cost and expenses$717.6M$628.3M$535M$435.5M$341M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$6.95M$13.4M$14.3M$14.7M$12.5M
Depreciation and amortization$504.9M$53.4M$32.7M$17.3M$11.6M
Ebitda-$-34.2M-$-242.77M-$-271.12M-$-282.24M-$-250.76M
Operating income-$-557.56M-$-474.31M-$-334.47M-$-307.2M-$-210.44M
Total other income/expenses, net$11.5M$164.8M$16.3M-$-7.05M-$-64.44M
Income before tax-$-546.06M-$-309.54M-$-318.16M-$-314.25M-$-274.87M
Income tax expense$320K$320K-$-11.42M$0.00-$-93.65M
Net income-$-546.38M-$-309.85M-$-306.74M-$-314.25M-$-181.22M
Weighted average shares outstanding$300M$274.5M$253.6M$224.6M$203.6M
Weighted average diluted shares outstanding$300M$288.4M$253.6M$224.6M$204.1M
Balance sheet
20252024202320222021
Cash and short-term investments$279.5M$389.9M$631.4M$772.3M$1.04B
Net receivables$35.5M$27.5M$36.6M$18.8M$24.2M
Inventory$49.3M$58.8M$56.7M$50.4M$24.6M
Total current assets$375M$495.7M$742.1M$852.1M$1.1B
Property, plant and equipment, net$65.8M$46.6M$69M$81.3M$79.1M
Goodwill and intangible assets$332.9M$707.3M$919.3M$820.2M$821M
Long-term investments$1.53M$0.00$0.00$0.00$0.00
Total non-current assets$409.1M$764.8M$1B$915M$905.8M
Total assets$784.1M$1.26B$1.75B$1.77B$2.01B
Accounts payable$20.8M$16.6M$15.1M$12M$11M
Short-term debt$900K$10M$10.1M$10.7M$9.32M
Deferred revenue$0.00$13.9M$16.3M$30.5M$11M
Total current liabilities$54.4M$66.3M$95M$263.3M$71.7M
Long-term debt$759.5M$662.4M$923.9M$937.8M$946M
Deferred revenue, non-current$19.9M$5.9M$5.53M$1.79M$25.1M
Total non-current liabilities$724.3M$687.6M$949.7M$940.9M$1.14B
Capital lease obligations$57.5M$24.9M$41.2M$50M$57.7M
Total liabilities$778.7M$753.9M$1.04B$1.2B$1.22B
Common stock$300K$290K$270K$230K$220K
Retained earnings-$-2.7B-$-2.15B-$-1.84B-$-1.53B-$-1.22B
Accumulated other comprehensive income (loss)$460K$420K$220K-$-4.76M-$-1.09M
Total equity$5.35M$506.6M$701.3M$562.9M$791M
Total investments$217.3M$334.6M$451.5M$447.2M$583.7M
Total debt$759.5M$672.4M$933.9M$948.5M$955.4M
Net debt$695.8M$617.1M$754M$623.4M$494.6M
Cash flow statement
20252024202320222021
Net income-$-546.38M-$-309.85M-$-306.74M-$-314.25M-$-181.22M
Depreciation and amortization$386.4M$53.3M$32.7M$17.3M$11.6M
Stock-based compensation$41.7M$0.00$0.00$78.6M$80.7M
Change in working capital$4.44M-$-40.58M-$-58.96M-$-53.97M$21M
Accounts receivable-$-7.92M$9.09M-$-17.83M$5.46M-$-7.17M
Inventory-$-1.42M-$-8.32M-$-13.84M-$-33.91M-$-12.43M
Accounts payable$2.48M$1.41M$210K$1.02M$6.36M
Net cash provided by operating activities-$-111.21M-$-206.06M-$-266.55M-$-263.21M-$-111.18M
Investments in property, plant and equipment-$-2.71M-$-6.19M-$-8.84M-$-16.93M-$-5.93M
Acquisitions, net$0.00$0.00-$-100K$180K-$-319.79M
Net cash used for investing activities$115.5M$124M$4.6M$116.1M-$-678.53M
Common stock issued$3.43M$7.7M$204.5M$11.2M$294.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$3.43M-$-42.99M$116.3M$9.62M$1.17B
Net change in cash$7.67M-$-124.15M-$-145.18M-$-137.51M$379.9M
Cash at end of period$63.7M$56.1M$180.2M$328.3M$465.8M
Operating cash flow-$-111.21M-$-206.06M-$-266.55M-$-263.21M-$-111.18M
Capital expenditure-$-2.71M-$-6.19M-$-8.84M-$-16.93M-$-5.93M
Free cash flow-$-113.92M-$-212.25M-$-275.39M-$-280.14M-$-117.11M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pacific Biosciences of California, Inc.

        Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

        CEO
        Christian O. Henry
        Employees
        485
        Beta
        2.29

        Explore

        Frequently asked questions

        What is the intrinsic value of Pacific Biosciences of California, Inc. (PACB)?

        Pacific Biosciences of California, Inc. (PACB) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PACB undervalued?

        PACB trades at a price of $1.63 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.